Barclays’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-5,500
| Closed | -$346K | – | 6408 |
|
|
2020
Q1 | $346K | Buy |
5,500
+4,600
| +511% | +$413K | ﹤0.01% | 3875 |
|
|
2019
Q4 | $112K | Buy |
900
+100
| +13% | +$8.95K | ﹤0.01% | 5421 |
|
|
2019
Q3 | $53K | Sell |
800
-100
| -11% | -$6.71K | ﹤0.01% | 5886 |
|
|
2019
Q2 | $72K | Sell |
900
-1,900
| -68% | -$170K | ﹤0.01% | 5912 |
|
|
2019
Q1 | $313K | Sell |
2,800
-200
| -7% | -$21.9K | ﹤0.01% | 4498 |
|
|
2018
Q4 | $302K | Buy |
3,000
+2,600
| +650% | +$269K | ﹤0.01% | 4282 |
|
|
2018
Q3 | $51K | Buy |
400
+100
| +33% | +$10.6K | ﹤0.01% | 6076 |
|
|
2018
Q2 | $25K | Sell |
300
-200
| -40% | -$14.6K | ﹤0.01% | 6063 |
|
|
2018
Q1 | $31K | Sell |
500
-81,700
| -99% | -$4.92M | ﹤0.01% | 6229 |
|
|
2017
Q4 | $4.8M | Buy |
82,200
+59,200
| +257% | +$3.73M | ﹤0.01% | 1682 |
|
|
2017
Q3 | $1.33M | Buy |
23,000
+2,500
| +12% | +$269K | ﹤0.01% | 2734 |
|
|
2017
Q2 | $2.48M | Sell |
20,500
-13,500
| -40% | -$1.56M | ﹤0.01% | 2063 |
|
|
2017
Q1 | $3.85M | Hold |
34,000
| – | – | ﹤0.01% | 1513 |
|
|
2016
Q4 | $3.69M | Buy |
34,000
+23,800
| +233% | +$2.84M | ﹤0.01% | 1607 |
|
|
2016
Q3 | $1.68M | Sell |
10,200
-8,000
| -44% | -$1.26M | ﹤0.01% | 2141 |
|
|
2016
Q2 | $2.6M | Buy |
+18,200
| New | +$2.65M | ﹤0.01% | 1804 |
|
|
2015
Q2 | – | Sell |
-10,000
| Closed | -$2.82M | – | 7266 |
|
|
2015
Q1 | $2.82M | Sell |
10,000
-20,000
| -67% | -$4.33M | ﹤0.01% | 2004 |
|
|
2014
Q4 | $4.68M | Buy |
+30,000
| New | +$5.54M | ﹤0.01% | 1754 |
|
|
2014
Q3 | – | Sell |
-2,000
| Closed | -$472K | – | 7871 |
|
|
2014
Q2 | $472K | Sell |
2,000
-89,500
| -98% | -$23.6M | ﹤0.01% | 4042 |
|
|
2014
Q1 | $30.1M | Buy |
+91,500
| New | +$30.9M | 0.03% | 484 |
|
Barclays's ICPT Position: Q4 2023 in Review
Barclays sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 178,438 shares — an estimated $3.31M sold.
Barclays first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $15.7M in Q1 2020. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Barclays reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Barclays sold 178,438 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $3.31M.
- Barclays first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Barclays's Intercept Pharmaceuticals, Inc. position peaked at $15.7M in Q1 2020.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.